Volume : 12, Issue : 09, September – 2025
Title:
A COMPREHENSIVE REVIEW ON “UNLOCK SUPERIOR EYE HEALTH: WHY INSITU-GELS ARE A GAME CHANGER
Authors :
Archana AS, Prof.(Dr.) John Wesley ,Prof. (Dr.) Mathan S, Prof. (Dr.) Shaiju S Dharan
Abstract :
The conventional treatment of ophthalmic diseases primarily focused on the topical application of eye drops. However, these formulations often exhibit low bioavailability and limited therapeutic efficacy due to rapid precorneal elimination mechanisms such as drainage and tear turnover. To address these challenges, in situ gelling systems have been developed. These systems are administered as liquid drops but undergo a sol-to-gel transition upon contact with the ocular surface, typically triggered by physiological factors like pH, temperature, or ionic strength. This transition enhances the residence time of the drug in the precorneal area, thereby improving its bioavailability and therapeutic response. In this context, the present study focuses on the formulation and evaluation of an ophthalmic delivery system for insitu activated gel system. These drug delivery systems are based on the principle of pH-triggered in situ gelation, using polymers such as polyacrylic acid (Carbapol 940) as gelling agent and HPMC K4M and HPMC K15M) as viscosity enhancers. This approach aims to provide a sustained release of the drug, thereby prolonging its therapeutic effect and enhancing patient compliance.
Cite This Article:
Please cite this article in press Archana AS et al., A Comprehensive Review On “Unlock Superior Eye Health: Why Insitu-Gels Are A Game Changer., Indo Am. J. P. Sci, 2025; 12(09).
REFERENCES:
1. Pandey M, Choudhury H, binti Abd Aziz A, Bhattamisra SK, Gorain B, Su JS, Tan CL, Chin WY, Yip KY. Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery: Recent progress and contemporary research. Polymers. 2021 Apr 20; 13(8):1340.
2. Paul S, Majumdar S, Chakraborty M. Revolutionizing ocular drug delivery: recent advancements in in situ gel technology. Bulletin of the National Research Centre. 2023 Oct 23; 47(1):154.
3. Ahmed B, Jaiswal S, Naryal S, Shah RM, Alany RG, Kaur IP. In situ gelling systems for ocular drug delivery. Journal of Controlled Release. 2024 Jul 1; 371:67-84.
4. Mandeep S, Dhruv D, DN P. A Recent Overview: In Situ Gel Smart Carriers for Ocular Drug Delivery. Journal of Drug Delivery & Therapeutics. 2021 Nov 2; 11(6-S):195- 205.
5. Sebastian ET. The complexity and origins of the human eye: A brief study on the anatomy, physiology, and origin of the eye.
6. Alamy.com
7. Patel PB, Shastri D, Shelat P, Shukla A. Ophthalmic drug delivery system: challenges and approaches. Systematic Reviews in Pharmacy. 2010 Jul 1;1(2):113.
8. Raj VK, Mazumder RU, Madhra MO. Ocular drug delivery system: challenges and approaches. Int J Appl Pharm. 2020; 12(5):49-57.
9. Mandal S, Shiva K, Kumar KP, Goel S, Patel RK, Sharma S, Chaudhary R, Bhati A, Pal N, Dixit AK. Ocular drug delivery system (ODDS): Exploration the challenges and approaches to improve ODDS. Journal of Pharmaceutical and Biological Sciences. 2021 Jul 1; 9(2):88-94.
10. Singh V, Ahmad R, Heming T. The challenges of ophthalmic drug delivery: a review. International Journal of Drug Discovery. 2011; 3(1):56-62.
11. Ahmed S, Amin MM, Sayed S. Ocular drug delivery: a comprehensive review. AAPS Pharm SciTech. 2023 Feb 14; 24(2):66.
12. Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic Nano emulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery. J Control Release. 2020; 328:895-916.
13. Ahmed S, Amin MM, El-Korany SM, Sayed S. Corneal targeted fenticonazole nitrate- loaded novasomes for the management of ocular candidiasis: preparation, in vitro characterization, ex vivo and in vivo assessments. Drug Deliv. 2022; 29(1):2428–41.
14. Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert opinion on biological therapy. 2003 Feb 1; 3(1):45-56.
15. Elsayed I, Sayed S. Tailored nanostructured platforms for boosting Trans corneal permeation: Box–Behngan statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization. International Journal of Nano medicine. 2017 Oct 30:7947-62.
16. Chan KC, Yu Y, Ng SH, Mak HK, Yip YW, van der Merwe Y, Ren T, Yung JS, Biswas S, Cao X, Chau Y. Intracameral injection of a chemically cross-linked hydrogel to study chronic neuro degeneration in glaucoma. Acta biomaterialia. 2019 Aug 1; 94:219-31.
17. Battiston K, Parrag I, Statham M, Louka D, Fischer H, Mackey G, Daley A, Gu F, Baldwin E, Yang B, Muirhead B. Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery. Nature Communications. 2021 May 17; 12(1):2875.
18. Safi M, Ang MJ, Patel P, Silkiss RZ. Rhino-orbital-cerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retro bulbar amphotericin B. American journal of ophthalmology case reports. 2020 Sep 1; 19:100771.
19. Anderson RL, Caplan A, Schuman JS. Ethical considerations for performing intraocular surgery on eyes with no light perception. Ophthalmology. 2019 Jan 1; 126(1):10-2.
20. Hayashi K, Hayashi H. Intravitreal versus retro bulbar injections of triamcinolone for macular oedema associated with branch retinal vein occlusion. American journal of ophthalmology. 2005 Jun 1; 139(6):972-82.
21. Wong CW, Czarny B, Metselaar JM, Ho C, Ng SR, Barathi AV, Storm G, Wong TT. Evaluation of Subconjunctival liposomal steroids for the treatment of experimental uveitis. Scientific reports. 2018 Apr 26; 8(1):6604.
22. Salama HA, Ghorab M, Mahmoud AA, Abdel Hady M. PLGA nanoparticles as Subconjunctival injection for management of glaucoma. Aaps Pharm SciTech. 2017 Oct; 18:2517-28.
23. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, Garcia EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A. Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. The ocular surface. 2019 Apr 1; 17(2):285-94.
24. Yiu G, Chung SH, Moll Hoff IN, Nguyen UT, Thomasy SM, Yoo J, Taraborelli D, Noronha G. Suprachoroidal and sub retinal injections of AAV using transcleral micro needles for retinal gene delivery in nonhuman primates. Molecular Therapy Methods & Clinical Development. 2020 Mar 13; 16:179-91.
25. Sobaci G, Tuncer K, Taş A, Özyurt M, Bayer A, Kutlu U. The effect of intraoperative antibiotics in irrigating solutions on aqueous humor contamination and endophthalmitis after phacoemulsification surgery. European journal of ophthalmology. 2003 Nov; 13(9-10):773-8.
26. Walter K, Delwadia N, Coben J. Continuous Intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract surgery: Reduction in surgical time and iris manipulation. Journal of Cataract & Refractive Surgery. 2019 Apr 1; 45(4):465-9.
27. Jung JH, Chiang B, Grossniklaus HE, Prausnitz MR. Ocular drug delivery targeted by iontophoresis in the suprachoroidal space using a micro needle. Journal of Controlled Release. 2018 May 10; 277:14-22.
28. Chen Y, Kalia YN. Short-duration ocular iontophoresis of ionisable acyclovir Prodrugs: A new approach to treat herpes simplex infections in the anterior and posterior segments of the eye. International journal of pharmaceutics. 2018 Jan 30; 536(1):292- 300.
29. Rathore KS, Nema RK. An insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res. 2009 Apr; 1(1):1-5.
30. Polish Pharmacopoeia, vol.8, part1, The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland, 2008.
31. Tangri P, Khurana S. Basics of ocular drug delivery systems. International Journal of Research in Pharmaceutical and Biomedical Sciences. 2011 Oct; 2(4):1541-52.
32. Yamaguchi M, Yasueda SI, Isowaki A, Yamamoto M, Kimura M, Inada K, Ohtori A. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. International journal of pharmaceutics. 2005 Sep 14; 301(1-2):121- 8.
33. Kapoor Y, Chauhan A. Ophthalmic delivery of Cyclosporine A from Brij-97 micro emulsion and surfactant-laden p-HEMA hydrogels. International journal of pharmaceutics. 2008 Sep 1; 361(1-2):222-9.
34. Shen J, Gan L, Zhu C, Zhang X, Dong Y, Jiang M, Zhu J, Gan Y. Novel NSAIDs ophthalmic formulation: flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect. International journal of pharmaceutics. 2011 Jun 30; 412(1- 2):115-22.
35. Järvinen T, Järvinen K. Prodrugs for improved ocular drug delivery. Advanced drug delivery reviews. 1996 May 22; 19(2):203-24.
36. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharmaceutical research. 2009 May; 26:1197-216.
37. Stefánsson E, Loftsson T. Cyclodextrin in eye drop formulations. Journal of inclusion phenomena and macro cyclic chemistry. 2002 Dec; 44:23-7.
38. Jung HJ, Abou-Jaoude M, Carbia BE, Plummer C, Chauhan A. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. Journal of controlled release. 2013 Jan 10; 165(1):82-9.
39. Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartrate: preparation and in vitro/in vivo evaluation. Aaps Pharm SciTech. 2011 Dec; 12:1335-47.
40. Ratnam GV, Madhavi S, Rajesh P. Ocular drug delivery: an update review. International journal of pharmacy and biological sciences. 2011; 1(4):437-46.
41. Shivhare R, Pathak A, Shrivastava N, Singh C, Tiwari G, Goyal R. An update review on novel advanced ocular drug delivery system. World Journal of Pharmacy and Pharmaceutical Sciences. 2012 Jul 15;1(2):545-68.
42. Maichuk YF. Ophthalmic drug inserts. Investigative Ophthalmology & Visual Science. 1975 Feb 1; 14(2):87-90.
43. Karthikeyan D, Bhowmick M, Pandey VP, Nandhakumar J, Sengottuvelu S, Sonkar S, Siva Kumar T. The concept of ocular inserts as drug delivery systems: An overview. Asian Journal of Pharmaceutics (AJP). 2008; 2(4).
44. Al-Tamimi DJ, Ammoo AM, Alani ME, Ibraheem JJ. Review Article Ophthalmic Dosage Forms. Karbala Journal of Pharmaceutical Sciences. 2020 Jul 1(18).
45. Kelly JA, Molyneux PD, Smith SA, Smith SE. Relative bioavailability of pilocarpine from a novel ophthalmic delivery system and conventional eye drop formulations. British journal of ophthalmology. 1989 May 1; 73(5):360-2.
46. Diestelhorst M, Krieglstein GK. The ocular tolerability of a new ophthalmic drug delivery system (NODS). International ophthalmology. 1994 Jan; 18:1-4.
47. Weyenberg W, Vermeire A, Vandervoort J, Remon JP, Ludwig A. Effects of roller compaction settings on the preparation of bio adhesive granules and ocular Minitablets. European journal of pharmaceutics and bio pharmaceutics. 2005 Apr 1; 59(3):527-36.
48. Moosa RM, Choonara YE, du Toit LC, Kumar P, Carmichael T, Tomar LK, Tyagi C, Pillay V. A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye. Journal of Pharmacy and Pharmacology. 2014 Apr; 66(4):490-506.
49. Abd EL-Gawad HA, Soliman OA, Barker SA, Girgis GN. Formulation and evaluation of gel forming ocular Minitablets containing Piroxicam. British Journal of Pharmaceutical Research. 2012 Jul 1; 2(3):141.
50. Ghadjahani Y, Mahmoodi H, Mortazavi A, Jaffariazar Z. The formulation of ocular timolol maleate Minitablets. Research in Pharmaceutical Sciences. 2012 Sep 2; 7(5):394.
51. Mortazavi SA, Jaffariazar Z, Damercheli E. Formulation and in-vitro evaluation of ocular ciprofloxacin-containing Minitablets prepared with different combinations of Carbapol 974P and various cellulose derivatives. Iranian Journal of Pharmaceutical Research: IJPR. 2010; 9(2):107.
52. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. Journal of controlled release. 2009 May 21; 136(1):2-13.
53. Bucolo C, Drago F, Salomone S. Ocular drug delivery: a clue from nanotechnology. Frontiers in pharmacology. 2012 Oct 25; 3:188.
54. Sahoo SK, Dilnawaz F, Krishna Kumar S. Nanotechnology in ocular drug delivery. Drug discovery today. 2008 Feb 1; 13(3-4):144-51.
55. Mudgil M, Gupta N, Nagpal M, Pawar P. Nanotechnology: a new approach for ocular drug delivery system. Int J Pharm Sci. 2012 Feb 11; 4(2):105-2.
56. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. International journal of pharmaceutics. 2004 Jan 9; 269(1):1-4.
57. Malik A. Tool for drug delivery. Advances in biological research. 2012; 6(4).
58. Vandamme TF, Brobeck L. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. Journal of controlled release. 2005 Jan 20; 102(1):23-38.
59. Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. Journal of pharmaceutical sciences. 2008 Jan 1; 97(1):123-43.
60. Nair AB, Shah J, Jacob S, Al-Dhubiab BE, Sreeharsha N, Morsy MA, Gupta S, Attimarad M, Shinu P, Venugopala KN. Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. PLoS one. 2021 Mar 19; 16(3):e0248857.
61. Sadeq ZA, Sabri LA, Al-Kinani KK. Natural polymer Effect on gelation and rheology of ketotifen loaded pH-sensitive in situ ocular gel (Carbapol). Journal of Advanced Pharmacy Education and Research. 2022; 12 (2): 45–50.https://doi.
org/10.51847/zof4tcfekt. 2022.
62. El-Feky YA, Fares AR, Zayed G, El-Telbany RF, Ahmed KA, El-Telbany DF. Repurposing of nifedipine loaded in situ ophthalmic gel as a novel approach for glaucoma treatment. Biomedicine & Pharmacotherapy. 2021 Oct 1; 142:112008.
63. Chowhan A, Giri TK. Polysaccharide as renewable responsive biopolymer for in situ gel in the delivery of drug through ocular route. International journal of biological macromolecules. 2020 May 1; 150:559-72.
64. Cassano R, Di Gioia ML, Trombino S. Gel-based materials for ophthalmic drug delivery. Gels. 2021 Aug 29;7(3):130.
65. Nanjwade BK, Manjappa AS, Murthy RS, Pol YD. A novel pH-triggered in situ gel for sustained ophthalmic delivery of ketorolac tromethamine. Asian J Pharm Sci. 2009; 4(3):189-99.
66. Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J, Lu J, Li J, Du S, Liu Z. Research progress of in-situ gelling ophthalmic drug delivery system. Asian journal of pharmaceutical sciences. 2019 Jan 1; 14(1):1-5.
67. Mitan R, Gokul Gandhi Jolly R, Parikh MB, Dharmesh MM. A pH triggered in-situ gel forming ophthalmic drug delivery system for tropicamide. Drug Deliv Technol. 2007; 5:44-9.
68. Srividya B, Cardoza RM, Amin PD, Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001; 73(2‐3):205‐11.
69. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. European journal of pharmaceutical sciences. 1998 Apr 1; 6(2):105-12.
70. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. International journal of pharmaceutics. 2002 Jul 8; 241(1):47-55.
71. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of Gelrite® gellan gum-based ocular delivery system for indomethacin. ACTA PHARMACEUTICA-ZAGREB-. 2003 Dec 1; 53(4):251-62.
72. Carlfors J, Edsman K, Petersson R, Jörnving K. Rheological evaluation of Gelrite® in situ gels for ophthalmic use. European journal of pharmaceutical sciences. 1998 Apr 1; 6(2):113-9.
73. Pandit JK, Bharathi D, Srinatha A, Ridhurkar DN, Singh S. Long acting ophthalmic formulation of indomethacin: evaluation of alginate gel systems. Indian journal of pharmaceutical sciences. 2007 Jan 1; 69(1).
74. Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. International journal of pharmaceutics. 2000 Apr 20; 199(2):119-27.
75. Kashyap N, Viswanad B, Sharma G, Bhardwaj V, Ramarao P, Kumar MR. Design and evaluation of biodegradable, bio sensitive in situ gelling system for pulsatile delivery of insulin. Biomaterials. 2007 Apr 1; 28(11):2051-60.
76. Sautou-Miranda V, Libert F, Grand-Boyer A, Gellis C, Chopineau J. Impact of deep freezing on the stability of 25 mg/ml vancomycin ophthalmic solutions. International journal of pharmaceutics. 2002 Mar 2; 234(1-2):205-12.
77. Rukari TG, Jadhav AS, Londhe RA, Phalke PL. A review on ophthalmic in situ gels. Am. J. Pharm. Tech. Res. 2019; 9:159-70.
78. Rathore KS, Nema RK. An insight into ophthalmic drug delivery system. Int J Pharm Sci Drug Res. 2009 Apr; 1(1):1-5.
79. Rathore KS, Nema RK. Management of Glaucoma: a review. Int. J. pharmtech res. 2009; 1(3):863-9.
80. Rukari TG, Jadhav AS, Londhe RA, Phalke PL. A review on ophthalmic in situ gels. Am. J. Pharm. Tech. Res. 2019; 9:159-70.